Multivariate analysis and odds ratio: measures of association between covariates and outcomes
| Covariates . | Outcome . | Multivariate analysis . | OR (95% CI) . |
|---|---|---|---|
| Patients enrolled from AAV cohort | Complete remission | P = 0.092 | 3.55 (CI 1.14, 11.09) |
| Partial remission | P > 0.05 | ||
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| Study design | Complete remission | P > 0.05 | |
| Case report | Partial remission | P > 0.05 | |
| Case series <5 patients | Steroid reductiona | P > 0.05 | |
| Case series ≥5 patients | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Age | Complete remission | P > 0.05 | |
| Partial remission | P > 0.05 | ||
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| EGPA diagnostic criteria | Complete remission | P > 0.05 | |
| ACR | Partial remission | P > 0.05 | |
| Others | Steroid reductiona | P > 0.05 | |
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| ANCA type | Complete remission | pANCA+ P = 0.053 | 3.97 (0.98, 16.01) |
| ANCA negative | Partial and remission | pANCA+ P = 0.78 | 0.667 (0.037, 12.16) |
| p-ANCA positive | Steroid reductiona | P > 0.05 | |
| c-ANCA | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Prevalent organ involvement | Complete remission | P > 0.05 | |
| Organs involved ≥2 and/or neuropathy | Partial remission | P > 0.05 | |
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| RTX schedule | Complete remission | P > 0.05 | |
| 2× 1000 mg | Partial remission | P > 0.05 | |
| 4× 375 mg | Steroid reductiona | P > 0.05 | |
| Others | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Concomitant therapy | Complete remission | P > 0.05 | |
| None | Partial remission | P > 0.05 | |
| Immunosuppressive drugs | Steroid reductiona | P > 0.05 | |
| Prednisone <7.5 mg/day | Death | P > 0.05 | |
| Others (plasmapheresis or Ig) | Relapse | P > 0.05 |
| Covariates . | Outcome . | Multivariate analysis . | OR (95% CI) . |
|---|---|---|---|
| Patients enrolled from AAV cohort | Complete remission | P = 0.092 | 3.55 (CI 1.14, 11.09) |
| Partial remission | P > 0.05 | ||
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| Study design | Complete remission | P > 0.05 | |
| Case report | Partial remission | P > 0.05 | |
| Case series <5 patients | Steroid reductiona | P > 0.05 | |
| Case series ≥5 patients | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Age | Complete remission | P > 0.05 | |
| Partial remission | P > 0.05 | ||
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| EGPA diagnostic criteria | Complete remission | P > 0.05 | |
| ACR | Partial remission | P > 0.05 | |
| Others | Steroid reductiona | P > 0.05 | |
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| ANCA type | Complete remission | pANCA+ P = 0.053 | 3.97 (0.98, 16.01) |
| ANCA negative | Partial and remission | pANCA+ P = 0.78 | 0.667 (0.037, 12.16) |
| p-ANCA positive | Steroid reductiona | P > 0.05 | |
| c-ANCA | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Prevalent organ involvement | Complete remission | P > 0.05 | |
| Organs involved ≥2 and/or neuropathy | Partial remission | P > 0.05 | |
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| RTX schedule | Complete remission | P > 0.05 | |
| 2× 1000 mg | Partial remission | P > 0.05 | |
| 4× 375 mg | Steroid reductiona | P > 0.05 | |
| Others | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Concomitant therapy | Complete remission | P > 0.05 | |
| None | Partial remission | P > 0.05 | |
| Immunosuppressive drugs | Steroid reductiona | P > 0.05 | |
| Prednisone <7.5 mg/day | Death | P > 0.05 | |
| Others (plasmapheresis or Ig) | Relapse | P > 0.05 |
Steroid reduction: prednisone ≤7.5 mg/day. AAV: ANCA-associated vasculitis; OR: odds ratio; EGPA: eosinophilic granulomatosis with polyangiitis; RTX: rituximab.
Multivariate analysis and odds ratio: measures of association between covariates and outcomes
| Covariates . | Outcome . | Multivariate analysis . | OR (95% CI) . |
|---|---|---|---|
| Patients enrolled from AAV cohort | Complete remission | P = 0.092 | 3.55 (CI 1.14, 11.09) |
| Partial remission | P > 0.05 | ||
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| Study design | Complete remission | P > 0.05 | |
| Case report | Partial remission | P > 0.05 | |
| Case series <5 patients | Steroid reductiona | P > 0.05 | |
| Case series ≥5 patients | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Age | Complete remission | P > 0.05 | |
| Partial remission | P > 0.05 | ||
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| EGPA diagnostic criteria | Complete remission | P > 0.05 | |
| ACR | Partial remission | P > 0.05 | |
| Others | Steroid reductiona | P > 0.05 | |
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| ANCA type | Complete remission | pANCA+ P = 0.053 | 3.97 (0.98, 16.01) |
| ANCA negative | Partial and remission | pANCA+ P = 0.78 | 0.667 (0.037, 12.16) |
| p-ANCA positive | Steroid reductiona | P > 0.05 | |
| c-ANCA | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Prevalent organ involvement | Complete remission | P > 0.05 | |
| Organs involved ≥2 and/or neuropathy | Partial remission | P > 0.05 | |
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| RTX schedule | Complete remission | P > 0.05 | |
| 2× 1000 mg | Partial remission | P > 0.05 | |
| 4× 375 mg | Steroid reductiona | P > 0.05 | |
| Others | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Concomitant therapy | Complete remission | P > 0.05 | |
| None | Partial remission | P > 0.05 | |
| Immunosuppressive drugs | Steroid reductiona | P > 0.05 | |
| Prednisone <7.5 mg/day | Death | P > 0.05 | |
| Others (plasmapheresis or Ig) | Relapse | P > 0.05 |
| Covariates . | Outcome . | Multivariate analysis . | OR (95% CI) . |
|---|---|---|---|
| Patients enrolled from AAV cohort | Complete remission | P = 0.092 | 3.55 (CI 1.14, 11.09) |
| Partial remission | P > 0.05 | ||
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| Study design | Complete remission | P > 0.05 | |
| Case report | Partial remission | P > 0.05 | |
| Case series <5 patients | Steroid reductiona | P > 0.05 | |
| Case series ≥5 patients | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Age | Complete remission | P > 0.05 | |
| Partial remission | P > 0.05 | ||
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| EGPA diagnostic criteria | Complete remission | P > 0.05 | |
| ACR | Partial remission | P > 0.05 | |
| Others | Steroid reductiona | P > 0.05 | |
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| ANCA type | Complete remission | pANCA+ P = 0.053 | 3.97 (0.98, 16.01) |
| ANCA negative | Partial and remission | pANCA+ P = 0.78 | 0.667 (0.037, 12.16) |
| p-ANCA positive | Steroid reductiona | P > 0.05 | |
| c-ANCA | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Prevalent organ involvement | Complete remission | P > 0.05 | |
| Organs involved ≥2 and/or neuropathy | Partial remission | P > 0.05 | |
| Steroid reductiona | P > 0.05 | ||
| Death | P > 0.05 | ||
| Relapse | P > 0.05 | ||
| RTX schedule | Complete remission | P > 0.05 | |
| 2× 1000 mg | Partial remission | P > 0.05 | |
| 4× 375 mg | Steroid reductiona | P > 0.05 | |
| Others | Death | P > 0.05 | |
| Relapse | P > 0.05 | ||
| Concomitant therapy | Complete remission | P > 0.05 | |
| None | Partial remission | P > 0.05 | |
| Immunosuppressive drugs | Steroid reductiona | P > 0.05 | |
| Prednisone <7.5 mg/day | Death | P > 0.05 | |
| Others (plasmapheresis or Ig) | Relapse | P > 0.05 |
Steroid reduction: prednisone ≤7.5 mg/day. AAV: ANCA-associated vasculitis; OR: odds ratio; EGPA: eosinophilic granulomatosis with polyangiitis; RTX: rituximab.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
